NASDAQ · Biotechnology

RNAZ (RNAZ) Stock

$3.96 -7.26% NASDAQ: RNAZ Healthcare

Valuation

MetricValue
Price$3.96
Market Cap$4.19M
P/E Ratio-0.12
P/B Ratio0.56
P/S Ratio0.00
EPS (TTM)$-52.59
52-Week High$20.99
52-Week Low$3.82
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-350.00%
ROA-21.60%
ROCE-280.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-19.0M$-19.0M$-16.0M$-28.0M
Net Profit$-7.0M$-18.0M$-19.0M$-17.0M$-35.0M
EPS$-648.00$-1080.00$-3453.53$-47.14$-52.59
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$23.0M$8.0M$5.0M$7.0M$162.0M
Total Liabilities$3.0M$4.0M$4.0M$9.0M$152.0M
Cash$21.0M$5.0M$3.0M$6.0M$18.0M
Borrowings$0$0$0$0$0

Latest News

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 PR Newswire · Jun 8, 2026 RNAZ: Introducing RNA Therapeutics Zacks Small Cap Research · Jun 8, 2026 TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a MT Newswires · Jun 3, 2026 TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer PR Newswire · Jun 3, 2026 EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study Benzinga · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-16.0M$-18.0M$-13.0M$-20.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$20.0M$-16.0M$-2.0M$3.0M$12.0M
Free Cash Flow$-6.0M$-16.0M$-18.0M$-13.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-89071.92%
Quick Ratio3.11
Interest Coverage—
Return 1Y-0.29%
Return 3Y-99.99%
Return 5Y-100.00%

Ownership

Insiders Held7.99%
Institutions Held6.85%
Institutions Float Held7.44%
Institutional HolderSharesReport Date
Geode Capital Management, LLC12,7402026-03-31
UBS Group AG8,2952026-03-31
Vanguard Capital Management LLC6,5452026-03-31
Vanguard Fiduciary Trust Co2,9822026-03-31
Tower Research Capital LLC (TRC)2282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
GLTODamora Therapeutics, Inc. $21.58 -3.36% -0.17 $34.47M 0.00%

About RNAZ

RNAZ is led by CEO Philippe Calais, publicly traded since 2021.

RNAZ stock trades at $3.96 with a market capitalization of $4.19M. The stock is valued at a price-to-earnings (P/E) ratio of -0.12, price-to-book of 0.56, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.82 and $20.99, and currently trades 81.1% below its 52-week high.

On profitability, RNAZ generates a return on equity (ROE) of -350.00%, return on capital employed of -280.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides